• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

健康声明申请编制与提交的科学和技术指南(第3版)

Scientific and technical guidance for the preparation and presentation of a health claim application (Revision 3).

出版信息

EFSA J. 2021 Mar 26;19(3):e06554. doi: 10.2903/j.efsa.2021.6554. eCollection 2021 Mar.

DOI:10.2903/j.efsa.2021.6554
PMID:33791038
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7996105/
Abstract

[Table: see text] Upon request from the European Commission, the scientific and technical guidance for the preparation and presentation of an application for authorisation of a health claim initially published in 2007 and subsequently revised in 2011 and 2016 has been updated. This guidance document presents a common format for the organisation of information for the preparation of a well-structured application for authorisation of health claims which fall under Articles 13(5), 14, and 19 of Regulation (EC) No 1924/2006. This guidance outlines: the information and scientific data which must be included in the application, the hierarchy of different types of data and study designs, and the key issues which should be addressed in the application to substantiate the health claim. This guidance has been revised in 2020 to inform applicants of new provisions in the pre-submission phase and in the application procedure set out in Regulation (EC) No 178/2002, as amended by Regulation (EU) 2019/1381 on the transparency and sustainability of the EU risk assessment in the food chain, that are applicable to all applications submitted as of 27 March 2021. The 2016 version of this guidance remains applicable to applications submitted before 27 March 2021.

摘要

[表格:见正文] 应欧盟委员会要求,最初于2007年发布、随后在2011年和2016年修订的健康声称授权申请编制和提交的科学技术指南已更新。本指南文件为编制符合(欧盟)第1924/2006号条例第13(5)条、第14条和第19条规定的结构良好的健康声称授权申请提供了信息组织的通用格式。本指南概述了:申请中必须包含的信息和科学数据、不同类型数据和研究设计的层级,以及申请中为证实健康声称应解决的关键问题。本指南于2020年进行了修订,以告知申请人2002年第178/2002号条例(经关于欧盟食物链风险评估透明度和可持续性的(欧盟)2019/1381号条例修订)中预提交阶段和申请程序的新规定,这些规定适用于2021年3月27日起提交的所有申请。本指南的2016年版本仍适用于2021年3月27日前提交的申请。

相似文献

1
Scientific and technical guidance for the preparation and presentation of a health claim application (Revision 3).健康声明申请编制与提交的科学和技术指南(第3版)
EFSA J. 2021 Mar 26;19(3):e06554. doi: 10.2903/j.efsa.2021.6554. eCollection 2021 Mar.
2
Scientific and technical guidance for the preparation and presentation of a health claim application (Revision 2).健康声明申请编制与提交的科学和技术指南(修订版2)
EFSA J. 2017 Jan 31;15(1):e04680. doi: 10.2903/j.efsa.2017.4680. eCollection 2017 Jan.
3
Guidance on the preparation and presentation of applications for exemption from mandatory labelling of food allergens and/or products thereof pursuant to Article 21 (2) of Regulation (EU) No 1169/2011.关于根据欧盟第1169/2011号法规第21(2)条申请豁免食品过敏原和/或其产品强制标签的准备和提交指南。
EFSA J. 2021 Mar 26;19(3):e06543. doi: 10.2903/j.efsa.2021.6543. eCollection 2021 Mar.
4
Scientific and technical guidance on foods for special medical purposes in the context of Article 3 of Regulation (EU) No 609/2013.关于欧盟第609/2013号法规第3条所涵盖的特殊医学用途食品的科学和技术指南。
EFSA J. 2021 Mar 26;19(3):e06544. doi: 10.2903/j.efsa.2021.6544. eCollection 2021 Mar.
5
General scientific guidance for stakeholders on health claim applications (Revision 1).利益相关者关于健康声称申请的一般科学指南(修订版1)。
EFSA J. 2021 Mar 26;19(3):e06553. doi: 10.2903/j.efsa.2021.6553. eCollection 2021 Mar.
6
Guidance on the preparation and submission of an application for authorisation of a novel food in the context of Regulation (EU) 2015/2283 (Revision 1).关于根据(欧盟)2015/2283号法规(修订版1)准备和提交新型食品授权申请的指南。
EFSA J. 2021 Mar 26;19(3):e06555. doi: 10.2903/j.efsa.2021.6555. eCollection 2021 Mar.
7
Guidance on the preparation and submission of the notification and application for authorisation of traditional foods from third countries in the context of Regulation (EU) 2015/2283 (Revision 1).关于在(欧盟)2015/2283号法规(修订版1)框架下准备和提交来自第三国传统食品的通报及授权申请的指南。
EFSA J. 2021 Mar 26;19(3):e06557. doi: 10.2903/j.efsa.2021.6557. eCollection 2021 Mar.
8
Scientific and technical guidance for the preparation and presentation of a dossier for evaluation of an infant and/or follow-on formula manufactured from protein hydrolysates (Revision 1).关于制备和提交用于评估由蛋白质水解物制成的婴儿配方奶粉和/或后续配方奶粉的档案的科学和技术指南(修订版1)
EFSA J. 2021 Mar 26;19(3):e06556. doi: 10.2903/j.efsa.2021.6556. eCollection 2021 Mar.
9
Scientific and technical guidance for the preparation and presentation of an application for authorisation of an infant and/or follow-on formula manufactured from protein hydrolysates.关于由蛋白质水解物制成的婴儿配方奶粉和/或后续配方奶粉授权申请的编制和提交的科学和技术指南。
EFSA J. 2017 May 11;15(5):e04779. doi: 10.2903/j.efsa.2017.4779. eCollection 2017 May.
10
Guidance on safety evaluation of sources of nutrients and bioavailability of nutrient from the sources (Revision 1).营养素来源的安全性评价及来源中营养素生物利用度指南(修订版1)
EFSA J. 2021 Mar 27;19(3):e06552. doi: 10.2903/j.efsa.2021.6552. eCollection 2021 Mar.

引用本文的文献

1
A systematic review of health promoting effects of consumption of whey-based fermented products on adults.一项关于食用基于乳清的发酵产品对成年人健康促进作用的系统评价。
Front Nutr. 2025 Aug 20;12:1651365. doi: 10.3389/fnut.2025.1651365. eCollection 2025.
2
Bioactive compounds in fermented foods: a systematic narrative review.发酵食品中的生物活性化合物:一项系统性叙述综述。
Front Nutr. 2025 Jul 2;12:1625816. doi: 10.3389/fnut.2025.1625816. eCollection 2025.
3
Phenolic compounds naturally present in olive oil and lowering of blood LDL-cholesterol and systolic blood pressure, therefore reducing the risk of coronary heart disease: Evaluation of a health claim pursuant to Article 14 of Regulation (EC) No 1924/2006.橄榄油中天然存在的酚类化合物与降低血液低密度脂蛋白胆固醇及收缩压,从而降低冠心病风险:依据欧盟第1924/2006号法规第14条对一项健康声明的评估
EFSA J. 2025 May 23;23(5):e9470. doi: 10.2903/j.efsa.2025.9470. eCollection 2025 May.
4
Olive oil polyphenols and the maintenance of normal HDL-cholesterol concentrations: Evaluation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006.橄榄油多酚与正常高密度脂蛋白胆固醇浓度的维持:依据欧盟第1924/2006号法规第13(5)条对一项健康声明的评估
EFSA J. 2025 May 2;23(5):e9372. doi: 10.2903/j.efsa.2025.9372. eCollection 2025 May.
5
Pacran®, a powder obtained from cranberries, and defence against bacterial pathogens in the lower urinary tract: Evaluation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006.Pacran®,一种从蔓越莓中提取的粉末,以及其对下尿路细菌病原体的防御作用:根据欧盟第1924/2006号法规第13(5)条对一项健康声明的评估
EFSA J. 2025 Apr 2;23(4):e9319. doi: 10.2903/j.efsa.2025.9319. eCollection 2025 Apr.
6
Creatine and improvement in cognitive function: Evaluation of a health claim pursuant to article 13(5) of regulation (EC) No 1924/2006.肌酸与认知功能改善:依据欧盟第1924/2006号法规第13(5)条对一项健康声明的评估
EFSA J. 2024 Nov 19;22(11):e9100. doi: 10.2903/j.efsa.2024.9100. eCollection 2024 Nov.
7
Prebiotics in food and dietary supplements: a roadmap to EU health claims.食品和膳食补充剂中的益生元:通往欧盟健康声称的路线图。
Gut Microbes. 2024 Jan-Dec;16(1):2428848. doi: 10.1080/19490976.2024.2428848. Epub 2024 Nov 15.
8
'Citicoline' and support of the memory function: Evaluation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006.“胞磷胆碱”与记忆功能支持:依据欧盟第1924/2006号法规第13(5)条对一项健康声明的评估
EFSA J. 2024 Jul 4;22(7):e8861. doi: 10.2903/j.efsa.2024.8861. eCollection 2024 Jul.
9
Joselito® and lowering of LDL-cholesterol concentration, blood pressure, and reduction of coronary heart disease risk: Evaluation of a health claim pursuant to Article 14 of Regulation (EC) No 1924/2006.乔塞利托®与低密度脂蛋白胆固醇浓度降低、血压降低以及冠心病风险降低:依据欧盟第1924/2006号法规第14条对一项健康声明的评估
EFSA J. 2024 Jul 4;22(7):e8862. doi: 10.2903/j.efsa.2024.8862. eCollection 2024 Jul.
10
Comparing technology and regulatory landscape of probiotics as food, dietary supplements and live biotherapeutics.比较益生菌作为食品、膳食补充剂和活体生物治疗剂的技术与监管环境。
Front Microbiol. 2023 Dec 19;14:1272754. doi: 10.3389/fmicb.2023.1272754. eCollection 2023.

本文引用的文献

1
General scientific guidance for stakeholders on health claim applications (Revision 1).利益相关者关于健康声称申请的一般科学指南(修订版1)。
EFSA J. 2021 Mar 26;19(3):e06553. doi: 10.2903/j.efsa.2021.6553. eCollection 2021 Mar.